| 0 (0%) | 09-27 14:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.16 | 1-year : | 15.37 |
| Resists | First : | 11.27 | Second : | 13.16 |
| Pivot price | 10.7 |
|||
| Supports | First : | 10.17 |
Second : | 9.49 |
| MAs | MA(5) : | 10.65 |
MA(20) : | 10.67 |
| MA(100) : | 9.43 |
MA(250) : | 8.79 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 53.8 |
D(3) : | 45.1 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 14.67 | Low : | 3.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ORIC ] has closed below upper band by 2.2%. Bollinger Bands are 59.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.21 - 11.28 | 11.28 - 11.34 |
| Low: | 10.22 - 10.29 | 10.29 - 10.37 |
| Close: | 11 - 11.12 | 11.12 - 11.23 |
Sat, 27 Sep 2025
Cantor Fitzgerald reiterates Overweight rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Nigeria
Thu, 25 Sep 2025
Palumbo Wealth Management LLC Takes Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Thu, 25 Sep 2025
Oric Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Tue, 23 Sep 2025
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study - MSN
Wed, 13 Aug 2025
Biotech layoffs: Fate, Generation Bio, ORIC trim teams and pipelines - FirstWord Pharma
Wed, 13 Aug 2025
Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 97 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 99.1 (%) |
| Shares Short | 8,170 (K) |
| Shares Short P.Month | 6,760 (K) |
| EPS | -1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.7 % |
| Return on Equity (ttm) | -43.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -5.89 |
| PEG Ratio | 0 |
| Price to Book value | 2.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|